Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:30:48.715Z.
Calculation as of: 2026-10-06T18:30:48.715Z.
Quote observation: 2026-10-06T18:30:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$510.38M
Price/OCF Ratio
372.54
TTM Avg
294.84
3Y Avg
294.84
5Y Avg
294.84
Market Cap
$509.10M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$521.64M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$500.98M
Price/OCF Ratio
16.40
TTM Avg
14.47
3Y Avg
11.25
5Y Avg
73.56
Market Cap
$524.77M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $512.21M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $510.38M | 372.54 | 294.84 | 294.84 | 294.84 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $521.64M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $522.16M | N/A | 0.26 | 0.26 | 0.26 |
| Tactile Systems Technology, Inc. (TCMD)vs › | $500.98M | 16.40 | 14.47 | 11.25 | 73.56 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $524.77M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $526.68M | N/A | N/A | N/A | N/A |
| Oculis Holding AG (OCS)vs › | $494.79M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $533.69M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
